ClinicalTrials.gg
Not yet recruitingNCT07939230ECHIDNAUpdated Nov 16, 2026

Evaluation of FLT3L Armoured CAR T-cells in HER2 Expressing Malignant Diseases in Adults

A Phase 1 interventional study of PMCC-COE-HER2FLT3L in HER-2 Positive Advanced Solid Tumors, HER-2 Positive Breast Cancer and HER-2 Positive Advanced Gastric Cancer, sponsored by Peter MacCallum Cancer Centre, Australia. Not yet recruiting at 1 site in Australia. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Peter MacCallum Cancer Centre, Australia · Phase 1, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 402 studies in Breast Neoplasms with a site in Australia — 84 open to participants now, 156 under way, 61 of them phase 3. Breast Neoplasms · Australia.

Planned enrollment
372nd of 380
12 · median 253
Started
2026
with 15 others
Phase 1
72 of 402
23 open now
Primary completion
2029-10
later than 135 of 155 live
Registered
401st of 402
by date

Among the 402 studies in Breast Neoplasms with a site in Australia, this one is the 372nd largest by planned enrollment of the 380 interventional ones that give a count, is one of 16 that started in 2026, is one of 72 in phase 1, reaches primary completion later than 135 of the 155 other live ones, and was the 401st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

84 of the 402 studies in Breast Neoplasms with a site in Australia are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 402 studies in Breast Neoplasms with a site in Australia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if a novel CAR-T cell therapy, called autologous PMCC-COE-HER2FLT3L CAR-T cells, is safe and effective at treating solid tumours that express high levels of the marker HER-2. Patients who have solid tumours that express the marker HER-2, and who have previously progressed or where unsuitable for current HER-2 targeted medications, will be recruited to the study. The PMCC-COE-HER2FLT3L CAR T-cells will be produced using LV and administered to patients after lymphodepleting conditioning chemotherapy. Patients will be then monitored for any side effects as a result of the CAR-T infusion and will have scans performed to assess how their tumour responds to the therapy.

Read the detailed description

This is a phase I dose escalation, open label, single centre study investigating the efficacy and safety of PMCC-COE-HER2FLT3L in patients with relapsed/refractory HER2 expressing malignancies.

Patients who meet all eligibility criteria will be registered on to the study with the intention to undergo leukapheresis for the manufacture of PMCC-COE-HER2FLT3L cells by Cell Therapies Pty, Ltd. In patients with progressing disease or, if symptom control is required, bridging therapy (investigator's choice) may be given during the PMCC-COE-HER2FLT3L manufacturing period (approximately 4-6 weeks).

Once supply of PMCC-COE-HER2FLT3L has been confirmed, patients will receive lymphodepleting chemotherapy with fludarabine (25 mg/m2 intravenous [IV]) and cyclophosphamide (250 mg/m2 IV) daily for 3 consecutive days. At the investigator's discretion, an alternative regimen of bendamustine 90 mg/m2 IV daily for 2 days may be used, or lymphodepleting chemotherapy may be dose-reduced or omitted.

Safety will be assessed by the occurrence of DLTs in the first 28 days, MT, AEs, and SAEs. Dose escalation will occur via an accelerated single patient dose escalation schema. Efficacy will be assessed by RECIST1.1 response criteria, PFS and OS.

03

Conditions studied

  • HER-2 Positive Advanced Solid Tumors
  • HER-2 Positive Breast Cancer
  • HER-2 Positive Advanced Gastric Cancer
  • HER-2 Positive Colorectal Cancer

Keywords

  • CAR-T
  • Chimeric Antigen Receptor (CAR) T-cells
  • HER-2 positive
  • HER-2 positive advanced solid tumors
  • PMCC-COE-HER2FLT3L
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient (and/or their legal guardian) has provided written using the ECHIDNA Patient Information and Consent Form (PICF)
  2. Age ≥ 16 years on the day of signing informed consent
  3. (ECOG) Performance Status score of 0 to 2 (Appendix 6)
  4. Patients should have unresectable, or disease based on most recent imaging. The following tumour types are eligible for this study:

    1. Patients with documented -positive breast cancer: Tumour must be HER2 in situ hybridisation (ISH)-positive by local testing using current American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) guidelines for scoring in breast cancer. Patients must have progressed after and/or are not suitable for a trastuzumab-containing treatment and trastuzumab deruxtecan per investigator assessment
    2. Patients with histologically documented gastric/gastroesophageal junction cancer: Tumour must be HER2 IHC 3+ or IHC 2 +/ISH-positive based on local tissue testing results in accordance with ASCO-CAP guidelines for scoring in gastroesophageal adenocarcinoma. Patients must have progressed after at least one prior trastuzumab-containing regimen
    3. Patients with histologically documented colorectal cancer: Tumour must be HER2 IHC 3+ or IHC 2+/ISH-positive based on local tissue testing results in accordance with ASCO-CAP guidelines for scoring in gastroesophageal adenocarcinoma. Patients must have progressed after available therapies including fluoropyrimidine based chemotherapy
    4. Other tumour types: Patients with histologically confirmed biliary tract cancer (including intra- or extrahepatic cholangiocarcinoma and tumours arising in the ampulla of Vater or gallbladder), cervical cancer, endometrial cancer, sarcoma, salivary duct carcinoma, and pancreatic adenocarcinoma. Tumour must be HER2 IHC 3+ or IHC 2+/ISH-positive based on local tissue testing results in accordance with ASCO-CAP guidelines for scoring in gastroesophageal adenocarcinoma. Patients must have progressed following at least one prior systemic treatment and have no satisfactory alternative treatment option as judged by the investigator

    Note: Patients who have had prior treatment with a HER2-targeting CAR T-cell therapies will be potentially eligible, if detectable HER2 expression on malignant cells can be demonstrated (per eligibility criterion #4) and at least 3 months has elapsed between the infusion of any prior cellular therapies and the infusion of the PMCC-COE-HER2FLT3L. If a prior HER2-targeting CAR T-cell therapy has been previously infused, baseline CAR T-cell quantification will be performed on peripheral blood prior to the infusion of PMCC-COE-HER2FLT3L, as outlined in the Schedule of Assessments at the Pre-Leukapheresis timepoint, Section 9.2.1)

  5. Have , as defined by RECIST1.1 (Appendix 1)
  6. Have a of ≥ 3 months, as judged by the investigator
  7. Adequate haematological function documented within 7 days prior to registration, defined as:

    • ≥ 80 g/L (peripheral red blood cell transfusion support is allowed)
    • (ANC) ≥ 1.0 x 109/L (granulocyte-colony stimulating factor [G-CSF] support is allowed, and ANC > 0.5 x 109/L is allowed if neutropenia is due to disease infiltration of bone marrow)
    • Absolute lymphocyte count (ALC) ≥ 0.1 x 109/L
    • ≥ 50 x 109/L
  8. Adequate cardiac function, defined as:

    • (LVEF) ≥ 50% on echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 90 days prior to registration
    • No suspicion for intercurrent deterioration in left ventricular function as assessed by the investigator
  9. Adequate pulmonary function, defined as:

    • Oxygen saturation measured by pulse oximetry ≥ 90% on room air
  10. Adequate renal function documented within 7 days prior to registration, defined as any one of:

    • A serum creatinine ≤ 1.5 x (ULN)
    • (CrCl) of ≥ 40 mL/min calculated by Cockcroft-Gault formula (Appendix 7)
    • CrCl ≥ 40 mL/min calculated by 24-hour urine collection
    • (GFR) ≥ 40 mL/min by renal scintigraphy
  11. Adequate hepatic function documented within 7 days prior to registration, defined as all of:

    • Total ≤ 1.5 x ULN (or ≤ 3.0 x ULN in patients with Gilbert's syndrome or documented liver involvement)
    • (ALT) ≤ 3.0 x ULN (or ≤ 5.0 x ULN in patients with documented liver involvement)
    • Aspartate aminotransferase (AST) ≤ 3.0 x ULN (or ≤ 5.0 x ULN in patients with documented liver involvement)
  12. Taking a maximum dose of 20 mg of oral prednisolone or equivalent
  13. Females of (FCBP) and non-sterile male patients (with partners of childbearing potential) must agree to use highly effective methods of from registration on the study to 2 months after the PMCC-COE-HER2FLT3L infusion or until PMCC-COE-HER2FLT3L is no longer present by quantitative PCR on two consecutive tests whichever is later. Effective methods of contraception are:

    • Total abstinence from sexual intercourse when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
    • Female sterilisation (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least 6 weeks prior to registration. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment
    • Male sterilisation (at least 6 months prior to screening), noting that for female patients on the study, the vasectomised male partner should be the sole partner for that patient
    • Use of oral, (oestrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system, or other forms of hormonal contraception that have comparable efficacy (failure rate \< 1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months prior to registration
    • Women are considered and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age-appropriate history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least 6 weeks prior to registration. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of childbearing potential
  14. Females of childbearing potential must have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test within 3 days prior to registration
  15. Sexually active male patients must use a condom during intercourse and must agree to refrain from sperm donation, from registration on the study until 12 months after PMCC-COE-HER2FLT3L infusion

Exclusion criteria

Exclusion Criteria:

  1. Active interstitial lung disease (ILD)/pneumonitis or history of (non-infectious) ILD/pneumonitis within 60 days prior to registration
  2. Uncontrolled pleural effusion(s), ascites or pericardial effusion that requires repeated drainage procedures
  3. Symptomatic, or active central nervous system (CNS) and/or carcinomatous meningitis

    Note 1: Patients with previously treated may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging, clinically stable, and without requirement of treatment for at least 14 days prior to registration. Anticonvulsant therapy at a stable dose is permitted

    Note 2: Patients with untreated brain metastases not requiring immediate local therapy are eligible provided all CNS lesions are \< 2.0 cm in maximal diameter on contrast brain MRI, they are clinically stable, and without requirement of steroid treatment for at least 14 days prior to registration. Anticonvulsant therapy at a stable dose is permitted

    Note 3: Patients with metastases to the midbrain, pons, medulla, or spinal cord are not eligible

  4. Patients with CNS disease who cannot undergo MRI assessment
  5. Patients with brain stem lesions
  6. Major surgery within 4 weeks prior to registration
  7. Receipt of a live, attenuated vaccine (except for COVID-19) within 4 weeks prior the planned commencement of lymphodepleting conditioning
  8. Receipt of any medical product within the last 30 days, or after 5 half-lives (whichever is the shortest) prior to planned leukapheresis
  9. cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure or myocardial infarction within 6 months of screening or class III to IV cardiac disease as defined by the Functional Classification
  10. Clinically significant neurological disorders (e.g., epilepsy, severe brain injury, dementia, Parkinson's disease, or /inflammatory disorders [e.g., Guillain-Barre syndrome, motor neuron disease, chronic inflammatory demyelinating polyneuropathy])
  11. History of other active , with the exception of:

    • Adequately treated in situ carcinoma of the cervix or breast
    • Adequately treated basal cell carcinoma of skin or localised squamous cell carcinoma of the skin
    • Low grade malignancies that are being observed and do not require treatment (e.g., low risk prostate cancer)
    • Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent and without evidence of recurrence for at least 2 years prior to registration
  12. Active or hepatitis A, B, or C infection

    • Patients who are positive for HIV by enzyme-linked immunosorbent assay or Western Blot, are ineligible
    • Patients who are seropositive for virus (HCV) are eligible if their most recent HCV DNA assay is undetectable (including those that have received curative therapy)
    • Patients who are seropositive for virus (HBV) due to prior infection may be eligible, if their most recent HBV DNA assay is undetectable, and suitable prophylactic therapy is given prior to and after treatment with PMCC-COE-HER2FLT3L (e.g., entecavir)
    • Patients who are seropositive for HBV because of vaccination (surface antibody positivity only) are eligible
  13. Other clinically significant active infection confirmed by clinical evidence, imaging, or positive laboratory tests (e.g., blood cultures, viral DNA/RNA by PCR)
  14. A known history or current autoimmune disease or other diseases resulting in permanent or requiring permanent immunosuppressive therapy (with the exception of corticosteroids up to 20 mg/day of oral prednisolone or equivalent)
  15. Current active (GVHD) requiring immunosuppression (with the exception of corticosteroids up to 20 mg/day of oral prednisolone or equivalent)
  16. Other significant life-threatening illness, medical condition, or laboratory abnormality that, in the opinion of the investigator, could compromise the patient's safety, impair their ability to receive PMCC-COE-HER2FLT3L, or put the study outcomes at undue risk
  17. Known to the of PMCC-COE-HER2FLT3L or to any product to be given to the patient as per the study protocol (e.g., tocilizumab and lymphodepleting agents)
  18. Women who are lactating
  19. Presence of any psychological, social, geographical, or other condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    PMCC-COE-HER2FLT3L

    Single dose of PMCC-COE-HER2FLT3L CAR-T cells administered following lymphodepleting chemotherapy

    Biological: PMCC-COE-HER2FLT3L

Interventions

  • BiologicalPMCC-COE-HER2FLT3L

    PMCC-COE-HER2FLT3L is an autologous CAR T-cell product that combines both HER2 targeting and FLT3L secretion.

06

What researchers measure

Primary outcomes

  1. Assess the safety of autologous PMCC-COE-HER2FLT3L in patients following lymphodepletion, including identification of the maximum tolerated dose (MTD)

    * Incidence, nature, and severity of adverse events (AEs) graded according to the Common Toxicity Criteria for Adverse Events Version 6.0 (CTCAE v6.0), and the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading for cytokine release syndrome (CRS) and Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS), and serious adverse events (SAEs) * Incidence, nature, and severity of "moderate" toxicity (MT) events and dose limiting toxicities (DLTs)

    Time frame: From enrolment until 28 days after administration of PMCC-COE-HER2FLT3L CAR-T cells

  2. Assess manufacturing feasibility of PMCC-COE-HER2FLT3L, defined as the percentage of patients in whom a suitable product manufactured, meeting pre-determined criteria for release.

    The patient has a suitable product manufactured, meeting pre-determined criteria for release (yes/no).

    Time frame: From enrolment until administration of the PMCC-COE-HER2FLT3L product

Secondary outcomes

  1. Assess the efficacy of a single dose of PMCC-COE-HER2FLT3L cells as assessed by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST1.1) by overall response

    Objective response (defined as: complete response \[CR\] or partial response \[PR\]) calculated as the proportion of patients with an objective response (CR or PR) at any stage after PMCC-COE-HER2FLT3L infusion per RECIST1.1

    Time frame: From enrolment to end of follow-up period (52 weeks after administration of PMCC-COE-HER2FLT3L CAR-T cells)

  2. Assess the efficacy of a single dose of PMCC-COE-HER2FLT3L cells as assessed by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST1.1) by duration of response

    Duration of response (months) defined as the time from first occurrence of a documented response (CR or PR) to the date of progression per RECIST1.1. Deceased patients without progression will be censored at the date of death

    Time frame: From enrolment to end of follow-up period (52 weeks after administration of PMCC-COE-HER2FLT3L CAR-T cells)

  3. Assess the efficacy of a single dose of PMCC-COE-HER2FLT3L cells as assessed by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST1.1) by progression free survival (PFS)

    Progression-free survival (months), measured from the date of PMCC-COE-HER2FLT3L infusion to the date of first progression at any site, as determined by the investigator according to RECIST1.1, or date of death due to any cause. Patients alive and progression free at the last efficacy follow-up visit will be censored at the date of the visit

    Time frame: From enrolment to end of follow-up period (52 weeks after administration of PMCC-COE-HER2FLT3L CAR-T cells)

  4. Determine persistence of PMCC-COE-HER2FLT3L in peripheral blood

    Persistence of PMCC-COE-HER2FLT3L in peripheral blood, as measured by flow cytometry and/or a quantitative polymerase chain reaction (PCR)

    Time frame: From enrolment until the end of the follow-up period (52 weeks after administration of PMCC-COE-HER2FLT3L CAR-T cells)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Oct 2029, 34 months later.

Of 372 non-industry phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 77. This study's planned 34 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2026
First posted
Nov 16, 2026
StartEst.
Nov 21, 2026
Primary completionEst.
Oct 1, 2029
CompletionEst.
Oct 1, 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939230
Lead sponsor
Peter MacCallum Cancer Centre, Australia
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 21, 2026 (estimated)
Primary completion
Oct 1, 2029 (estimated)
Completion
Oct 1, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Ruth Columbus, PhD
Contact
Ruth.Columbus@petermac.org
+61 3 8559 7364
Katherine Cummins, MBBS (Hons) PhD
principal investigator · Peter MacCallum Cancer Centre, Australia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion